Maze Therapeutics, Inc.
MAZE
$27.18
-$0.49-1.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 20.00M | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 20.00M | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 20.00M | -- | -- | -- |
| SG&A Expenses | 13.10M | 12.41M | 10.49M | 7.78M | 8.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.04M | 46.55M | 38.06M | 32.97M | 36.47M |
| Operating Income | -48.04M | -26.55M | -38.06M | -32.97M | -36.47M |
| Income Before Tax | -44.73M | -24.21M | -34.57M | -30.09M | -33.68M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.73M | -24.21M | -34.57M | -30.09M | -33.68M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.73M | -24.21M | -34.57M | -30.09M | -33.68M |
| EBIT | -48.04M | -26.55M | -38.06M | -32.97M | -36.47M |
| EBITDA | -47.64M | -26.11M | -37.56M | -32.39M | -35.83M |
| EPS Basic | -0.76 | -0.45 | -0.65 | -0.66 | -0.77 |
| Normalized Basic EPS | -0.47 | -0.28 | -0.40 | -0.41 | -0.48 |
| EPS Diluted | -0.76 | -0.45 | -0.65 | -0.66 | -0.77 |
| Normalized Diluted EPS | -0.47 | -0.28 | -0.40 | -0.41 | -0.48 |
| Average Basic Shares Outstanding | 59.00M | 53.90M | 53.40M | 45.78M | 43.80M |
| Average Diluted Shares Outstanding | 59.00M | 53.90M | 53.40M | 45.78M | 43.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |